Provider of ambulatory-focused technology solutions, NextGen Healthcare Inc (NASDAQ:NXGN) posted Q3 FY22 sales of $149.7 million, +6% Y/Y, beating the consensus of $146.32 million.
- Recurring revenue accounted for 90% of total revenue, or $134.5 million, growing 5% Y/Y.
- In Q3, subscription services revenue generated $41.2 million, up 8% Y/Y, driven by demand for NGE SaaS and Virtual Visit solutions.
- Q3 bookings, which reflect annual contract value, were $37.7 million.
- The company posted adjusted EPS of $0.24, down from $0.26 a year ago, and better than the consensus of $0.21.
- The overall gross margin remained unchanged at 50%. The company posted an operating income of $8 million compared to just $0.9 million a year ago.
- In October, the Board approved a $60 million share repurchase program.
- Guidance: NextGen raised FY22 sales guidance to $591 million - $595 million (compared to consensus of $588.23 million), from prior guidance of $584 million - $590 million.
- The company forecast FY22 adjusted EPS of $0.96 - $1.00 (vs. consensus of $0.95) up from the previous outlook of $0.90 - $0.96.
- Price Action: NXGN shares closed lower by 1.55% at $18.36 on Tuesday.
